Review



mdr1 p gp  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech mdr1 p gp
    Mdr1 P Gp, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 182 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mdr1+p+gp/P+glycoprotein+Antibody/pm41723828-254-38-69
    Average 96 stars, based on 182 article reviews
    mdr1 p gp - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Immunohistochemistry:

    Article Title: PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways
    Article Snippet: .. The levels of PD-L1 and MDR1/P-gp in breast cancer samples were assessed using IHC with anti-PD-L1 (Proteintech) and anti-MDR1/P-gp antibodies (Proteintech). ..

    Article Title: PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
    Article Snippet: .. The levels of PD-L1 and MDR1/P-gp in breast cancer samples were assessed using IHC with anti-PD-L1 (Proteintech) and anti-MDR1/P-gp antibodies (Proteintech). ..

    Blocking Assay:

    Article Title: Nanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4-Mediated Ferroptosis.
    Article Snippet: The processed protein samples were separated by SDS-PAGE and transferred onto PVDFmembranes (Millipore, USA). .. The membranes were blocked with a rapid blocking buffer (YamayBio, China) to prevent nonspecific binding and then incubated overnight at 4◦Cwith primary antibodies diluted according to the manufacturers’ instructions, including: Bcl-2 (12789-1-AP), Bax (50599-2-Ig), Cyclin-D3 (26755-1-AP), PCNA (10205-2-AP), MDR1/P-gp (22336-1-AP), ENT1 (29862-1-AP), RRM2 (11661-1- AP), DCK (17758-1-AP), ACTIN (66009-1-Ig), GAPDH (10494-1- AP), ACSL4 (22401-1-AP), SLC7A11 (26864-1-AP), GPX4 (67763-1- Ig), FTH1 (11682-1-AP), HSPB1 (18284-1-AP), and ubiquitin (10201- 2-AP) (all from Proteintech, China). .. After washing with TBST, the membranes were incubated with HRP-conjugated secondary antibodies (SA00001-1 or SA00001-2, Proteintech, China) for 1 h at room temperature on a shaker.

    Binding Assay:

    Article Title: Nanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4-Mediated Ferroptosis.
    Article Snippet: The processed protein samples were separated by SDS-PAGE and transferred onto PVDFmembranes (Millipore, USA). .. The membranes were blocked with a rapid blocking buffer (YamayBio, China) to prevent nonspecific binding and then incubated overnight at 4◦Cwith primary antibodies diluted according to the manufacturers’ instructions, including: Bcl-2 (12789-1-AP), Bax (50599-2-Ig), Cyclin-D3 (26755-1-AP), PCNA (10205-2-AP), MDR1/P-gp (22336-1-AP), ENT1 (29862-1-AP), RRM2 (11661-1- AP), DCK (17758-1-AP), ACTIN (66009-1-Ig), GAPDH (10494-1- AP), ACSL4 (22401-1-AP), SLC7A11 (26864-1-AP), GPX4 (67763-1- Ig), FTH1 (11682-1-AP), HSPB1 (18284-1-AP), and ubiquitin (10201- 2-AP) (all from Proteintech, China). .. After washing with TBST, the membranes were incubated with HRP-conjugated secondary antibodies (SA00001-1 or SA00001-2, Proteintech, China) for 1 h at room temperature on a shaker.

    Incubation:

    Article Title: Nanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4-Mediated Ferroptosis.
    Article Snippet: The processed protein samples were separated by SDS-PAGE and transferred onto PVDFmembranes (Millipore, USA). .. The membranes were blocked with a rapid blocking buffer (YamayBio, China) to prevent nonspecific binding and then incubated overnight at 4◦Cwith primary antibodies diluted according to the manufacturers’ instructions, including: Bcl-2 (12789-1-AP), Bax (50599-2-Ig), Cyclin-D3 (26755-1-AP), PCNA (10205-2-AP), MDR1/P-gp (22336-1-AP), ENT1 (29862-1-AP), RRM2 (11661-1- AP), DCK (17758-1-AP), ACTIN (66009-1-Ig), GAPDH (10494-1- AP), ACSL4 (22401-1-AP), SLC7A11 (26864-1-AP), GPX4 (67763-1- Ig), FTH1 (11682-1-AP), HSPB1 (18284-1-AP), and ubiquitin (10201- 2-AP) (all from Proteintech, China). .. After washing with TBST, the membranes were incubated with HRP-conjugated secondary antibodies (SA00001-1 or SA00001-2, Proteintech, China) for 1 h at room temperature on a shaker.

    Ubiquitin Proteomics:

    Article Title: Nanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4-Mediated Ferroptosis.
    Article Snippet: The processed protein samples were separated by SDS-PAGE and transferred onto PVDFmembranes (Millipore, USA). .. The membranes were blocked with a rapid blocking buffer (YamayBio, China) to prevent nonspecific binding and then incubated overnight at 4◦Cwith primary antibodies diluted according to the manufacturers’ instructions, including: Bcl-2 (12789-1-AP), Bax (50599-2-Ig), Cyclin-D3 (26755-1-AP), PCNA (10205-2-AP), MDR1/P-gp (22336-1-AP), ENT1 (29862-1-AP), RRM2 (11661-1- AP), DCK (17758-1-AP), ACTIN (66009-1-Ig), GAPDH (10494-1- AP), ACSL4 (22401-1-AP), SLC7A11 (26864-1-AP), GPX4 (67763-1- Ig), FTH1 (11682-1-AP), HSPB1 (18284-1-AP), and ubiquitin (10201- 2-AP) (all from Proteintech, China). .. After washing with TBST, the membranes were incubated with HRP-conjugated secondary antibodies (SA00001-1 or SA00001-2, Proteintech, China) for 1 h at room temperature on a shaker.



    Similar Products

    human mdr1 p gp  (Merck & Co)
    86
    Merck & Co human mdr1 p gp
    Human Mdr1 P Gp, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mdr1+p+gp/cells+llc+mdr1a+pk1/pm41740806-59-3-21
    Average 86 stars, based on 1 article reviews
    human mdr1 p gp - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    mdr1 p gp  (Proteintech)
    96
    Proteintech mdr1 p gp
    Mdr1 P Gp, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mdr1+p+gp/P+glycoprotein+Antibody/pm41723828-254-38-69
    Average 96 stars, based on 1 article reviews
    mdr1 p gp - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    p gp  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc p gp
    Impact of <t>P-gp,</t> <t>BCRP</t> and MRP4 on the pharmacokinetics of NTRC 0066-0. ( A ) Plasma concentration, brain concentration and brain–plasma ratio of NTRC 0066-0 following intravenous administration of 5 mg/kg to wild-type (WT), Abcb1a/b −/− , Abcg2 −/− , Abcb1a/b; Abcg2 −/− and Abcb1a/b; Abcg2;Abcc4 −/− mice. ( B ) Plasma and brain concentration–time curves following administration of 20 mg/kg NTRC 0066-0 p.o. to WT mice. ( C ) Plasma concentration–time curves following administration of 10 mg/kg NTRC0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. ( D ) Plasma concentration, brain concentration and brain–plasma ratio 24 h after administration of 10 mg/kg NTRC 0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. Data are mean ± SD; n ≥ 4; *** p < 0.001
    P Gp, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mdr1+p+gp/MDR1%2FABCB1+Rabbit+mAb/pmc12909347-100-29-32
    Average 95 stars, based on 1 article reviews
    p gp - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    p gp rabbit polyclonal antibody  (Bioss)
    91
    Bioss p gp rabbit polyclonal antibody
    Impact of <t>P-gp,</t> <t>BCRP</t> and MRP4 on the pharmacokinetics of NTRC 0066-0. ( A ) Plasma concentration, brain concentration and brain–plasma ratio of NTRC 0066-0 following intravenous administration of 5 mg/kg to wild-type (WT), Abcb1a/b −/− , Abcg2 −/− , Abcb1a/b; Abcg2 −/− and Abcb1a/b; Abcg2;Abcc4 −/− mice. ( B ) Plasma and brain concentration–time curves following administration of 20 mg/kg NTRC 0066-0 p.o. to WT mice. ( C ) Plasma concentration–time curves following administration of 10 mg/kg NTRC0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. ( D ) Plasma concentration, brain concentration and brain–plasma ratio 24 h after administration of 10 mg/kg NTRC 0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. Data are mean ± SD; n ≥ 4; *** p < 0.001
    P Gp Rabbit Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mdr1+p+gp/MDR1+Polyclonal+Antibody/pmc12666687-39-83-92
    Average 91 stars, based on 1 article reviews
    p gp rabbit polyclonal antibody - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier
    antibodies against p gp 13342s  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc antibodies against p gp 13342s
    Impact of <t>P-gp,</t> <t>BCRP</t> and MRP4 on the pharmacokinetics of NTRC 0066-0. ( A ) Plasma concentration, brain concentration and brain–plasma ratio of NTRC 0066-0 following intravenous administration of 5 mg/kg to wild-type (WT), Abcb1a/b −/− , Abcg2 −/− , Abcb1a/b; Abcg2 −/− and Abcb1a/b; Abcg2;Abcc4 −/− mice. ( B ) Plasma and brain concentration–time curves following administration of 20 mg/kg NTRC 0066-0 p.o. to WT mice. ( C ) Plasma concentration–time curves following administration of 10 mg/kg NTRC0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. ( D ) Plasma concentration, brain concentration and brain–plasma ratio 24 h after administration of 10 mg/kg NTRC 0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. Data are mean ± SD; n ≥ 4; *** p < 0.001
    Antibodies Against P Gp 13342s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mdr1+p+gp/MDR1%2FABCB1+Rabbit+mAb/pmc12562668-69-0-10
    Average 95 stars, based on 1 article reviews
    antibodies against p gp 13342s - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    anti p gp antibody  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology anti p gp antibody
    Impact of <t>P-gp,</t> <t>BCRP</t> and MRP4 on the pharmacokinetics of NTRC 0066-0. ( A ) Plasma concentration, brain concentration and brain–plasma ratio of NTRC 0066-0 following intravenous administration of 5 mg/kg to wild-type (WT), Abcb1a/b −/− , Abcg2 −/− , Abcb1a/b; Abcg2 −/− and Abcb1a/b; Abcg2;Abcc4 −/− mice. ( B ) Plasma and brain concentration–time curves following administration of 20 mg/kg NTRC 0066-0 p.o. to WT mice. ( C ) Plasma concentration–time curves following administration of 10 mg/kg NTRC0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. ( D ) Plasma concentration, brain concentration and brain–plasma ratio 24 h after administration of 10 mg/kg NTRC 0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. Data are mean ± SD; n ≥ 4; *** p < 0.001
    Anti P Gp Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mdr1+p+gp/MDR1+Antibody/pm40790816-67-7-14
    Average 96 stars, based on 1 article reviews
    anti p gp antibody - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    sb-mdr1/p-gp predeasy atpase kit  (Solvo Biotechnology)
    90
    Solvo Biotechnology sb-mdr1/p-gp predeasy atpase kit
    Impact of <t>P-gp,</t> <t>BCRP</t> and MRP4 on the pharmacokinetics of NTRC 0066-0. ( A ) Plasma concentration, brain concentration and brain–plasma ratio of NTRC 0066-0 following intravenous administration of 5 mg/kg to wild-type (WT), Abcb1a/b −/− , Abcg2 −/− , Abcb1a/b; Abcg2 −/− and Abcb1a/b; Abcg2;Abcc4 −/− mice. ( B ) Plasma and brain concentration–time curves following administration of 20 mg/kg NTRC 0066-0 p.o. to WT mice. ( C ) Plasma concentration–time curves following administration of 10 mg/kg NTRC0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. ( D ) Plasma concentration, brain concentration and brain–plasma ratio 24 h after administration of 10 mg/kg NTRC 0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. Data are mean ± SD; n ≥ 4; *** p < 0.001
    Sb Mdr1/P Gp Predeasy Atpase Kit, supplied by Solvo Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mdr1+p+gp/mdr1+mdck+cells/pm40603742-116-14-18
    Average 90 stars, based on 1 article reviews
    sb-mdr1/p-gp predeasy atpase kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Impact of P-gp, BCRP and MRP4 on the pharmacokinetics of NTRC 0066-0. ( A ) Plasma concentration, brain concentration and brain–plasma ratio of NTRC 0066-0 following intravenous administration of 5 mg/kg to wild-type (WT), Abcb1a/b −/− , Abcg2 −/− , Abcb1a/b; Abcg2 −/− and Abcb1a/b; Abcg2;Abcc4 −/− mice. ( B ) Plasma and brain concentration–time curves following administration of 20 mg/kg NTRC 0066-0 p.o. to WT mice. ( C ) Plasma concentration–time curves following administration of 10 mg/kg NTRC0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. ( D ) Plasma concentration, brain concentration and brain–plasma ratio 24 h after administration of 10 mg/kg NTRC 0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. Data are mean ± SD; n ≥ 4; *** p < 0.001

    Journal: Cellular Oncology (Dordrecht, Netherlands)

    Article Title: Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma

    doi: 10.1007/s13402-026-01175-9

    Figure Lengend Snippet: Impact of P-gp, BCRP and MRP4 on the pharmacokinetics of NTRC 0066-0. ( A ) Plasma concentration, brain concentration and brain–plasma ratio of NTRC 0066-0 following intravenous administration of 5 mg/kg to wild-type (WT), Abcb1a/b −/− , Abcg2 −/− , Abcb1a/b; Abcg2 −/− and Abcb1a/b; Abcg2;Abcc4 −/− mice. ( B ) Plasma and brain concentration–time curves following administration of 20 mg/kg NTRC 0066-0 p.o. to WT mice. ( C ) Plasma concentration–time curves following administration of 10 mg/kg NTRC0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. ( D ) Plasma concentration, brain concentration and brain–plasma ratio 24 h after administration of 10 mg/kg NTRC 0066-0 p.o. and i.p. to WT and Abcb1a/b; Abcg2 −/− mice. Data are mean ± SD; n ≥ 4; *** p < 0.001

    Article Snippet: Decalcified tissues were paraffin embedded and cut into 4 μm coronal sections that were stained with hematoxylin and eosin (H&E), and for human Vimentin (1:4,000; M0725; DakoCytomation; Glostrup, Denmark), P-gp (1:200; 13978; Cell Signaling Technology; Danvers, MA), BCRP (1:400; ab24115; Abcam; Cambridge, UK), mouse IgG (K4001, Dako) and MELpT-KNL1 (1:50; as described previously [ , ]).

    Techniques: Drug discovery, Clinical Proteomics, Concentration Assay

    Characterization of the intracranial orthotopic E98 GBM model. ( A ) Magnetic resonance imaging of an orthotopic E98 tumor using a sequence consisting of T2-weighted, T1-weighted pre-contrast and T1-weight gadolinium contrast-enhanced (T1 + Gd) imaging. ( B ) Coronal E98 tumor sections stained for hematoxylin and eosin (H&E), human vimentin (hVimentin), P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and immunoglobulin G (IgG)

    Journal: Cellular Oncology (Dordrecht, Netherlands)

    Article Title: Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma

    doi: 10.1007/s13402-026-01175-9

    Figure Lengend Snippet: Characterization of the intracranial orthotopic E98 GBM model. ( A ) Magnetic resonance imaging of an orthotopic E98 tumor using a sequence consisting of T2-weighted, T1-weighted pre-contrast and T1-weight gadolinium contrast-enhanced (T1 + Gd) imaging. ( B ) Coronal E98 tumor sections stained for hematoxylin and eosin (H&E), human vimentin (hVimentin), P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and immunoglobulin G (IgG)

    Article Snippet: Decalcified tissues were paraffin embedded and cut into 4 μm coronal sections that were stained with hematoxylin and eosin (H&E), and for human Vimentin (1:4,000; M0725; DakoCytomation; Glostrup, Denmark), P-gp (1:200; 13978; Cell Signaling Technology; Danvers, MA), BCRP (1:400; ab24115; Abcam; Cambridge, UK), mouse IgG (K4001, Dako) and MELpT-KNL1 (1:50; as described previously [ , ]).

    Techniques: Magnetic Resonance Imaging, Sequencing, Imaging, Staining